Supplementary Tables – Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study

<b>Supplementary Table S1. </b>Patient inclusion criteria<b> </b> <b>Supplementary Table S2. </b>Therapeutic indications for IBRANCE (palbociclib) in the EU <b>Supplementary Table S3. </b>Patient demographics and clinical characteristics for the nine individual EU countries<b></b> <b>Supplementary Table S4. </b>Palbociclib treatment patterns for the nine individual EU countries <b>Supplementary Table S5. </b>Response to palbociclib treatment for the nine individual EU countries Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study<b>补充表S1. </b>患者纳入标准<b> </b> <b>补充表S2. </b>欧盟境内哌柏西利（palbociclib，商品名IBRANCE）的治疗适应证 <b>补充表S3. </b>九个欧盟成员国的患者人口统计学特征及临床特征<b></b> <b>补充表S4. </b>九个欧盟成员国的哌柏西利治疗模式 <b>补充表S5. </b>九个欧盟成员国患者的哌柏西利治疗应答情况 HR+/HER2-晚期/转移性乳腺癌患者的哌柏西利真实世界治疗：欧洲IRIS研究